Axogen Inc (AXGN)

NASDAQ
Currency in USD
18.04
+0.14(+0.78%)
Closed
After Hours
18.040.00(0.00%)
AXGN Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
17.3818.29
52 wk Range
5.5521.00
Key Statistics
Edit
Prev. Close
17.9
Open
17.63
Day's Range
17.38-18.29
52 wk Range
5.55-21
Volume
350.05K
Average Vol. (3m)
536.51K
1-Year Change
133.07%
Book Value / Share
2.36
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AXGN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
25.71
Upside
+42.54%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period
Show more

Axogen Inc Company Profile

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.

Axogen Inc SWOT Analysis


Regulatory Catalyst
Potential BLA approval for Avance Nerve Graft in September 2025 could be a game-changer, with analyst price targets ranging from $24 to $26.
Strategic Growth Plan
Explore AxoGen's ambitious 15-20% revenue CAGR target for 2025-2028, driven by high-potential accounts and operational efficiencies.
Innovative Portfolio
Discover AxoGen's unique product lineup, including AxoGuard HA+ and Avive+, positioned with limited biologic competition in sizable markets.
Nerve Repair Pionee
AxoGen leads in peripheral nerve injury solutions, with a $5.6 billion addressable market and 17.8% year-over-year revenue growth, showcasing strong market potential.
Read full SWOT analysis

Axogen Inc Earnings Call Summary for Q4/2024

  • Q4 2024 EPS of $0.07 beat $0.03 forecast; revenue reached $49.4M, up 15.1% YoY; stock rose 2.61% premarket to $18.48
  • Net income of $400,000 in Q4, reversing $3.9M loss YoY; gross margin improved to 76.1% from 74.6% in Q4 2023
  • Company projects 15-17% revenue growth for 2025, aims to maintain 73-75% gross margin and be cash flow positive
  • Focus on expanding nerve repair algorithm across markets; exploring new opportunities like prostatectomy nerve repair
  • Anticipates BLA approval by September; confident in $5B Total Addressable Market estimate despite potential challenges
Last Updated: 02/25/2025, 09:23 AM
Read Full Transcript

Compare AXGN to Peers and Sector

Metrics to compare
AXGN
Peers
Sector
Relationship
P/E Ratio
−81.1x−2.2x−0.5x
PEG Ratio
−1.410.180.00
Price / Book
7.8x1.1x2.6x
Price / LTM Sales
4.3x1.6x3.0x
Upside (Analyst Target)
39.7%224.1%53.8%
Fair Value Upside
Unlock11.9%9.2%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 25.71
(+42.54% Upside)

Earnings

Latest Release
Feb 25, 2025
EPS / Forecast
0.07 / 0.03
Revenue / Forecast
49.40M / 47.58M
EPS Revisions
Last 90 days

People Also Watch

42.990
INOD
-2.14%
161.48
ESE
+0.34%
29.87
CARG
-0.13%
306.72
APP
+3.26%
219.44
CEG
+0.64%

FAQ

What Is the Axogen Inc (AXGN) Stock Price Today?

The Axogen Inc stock price today is 18.04

What Stock Exchange Does Axogen Inc Trade On?

Axogen Inc is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Axogen Inc?

The stock symbol for Axogen Inc is "AXGN."

What Is the Axogen Inc Market Cap?

As of today, Axogen Inc market cap is 801.74M.

What is Axogen Inc Earnings Per Share?

The Axogen Inc EPS is -0.225.

What Is the Next Axogen Inc Earnings Date?

Axogen Inc will release its next earnings report on Apr 30, 2025.

From a Technical Analysis Perspective, Is AXGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.